电邮这篇文章 Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens
- 作者: Kravchenko A.V.1, Kravchenko AV2
-
隶属关系:
- Федеральный научно-методический центр по профилактике и борьбе со СПИДом ФГУН Центральный НИИ эпидемиологии Роспотребнадзора
- Federal Research and Methodological Center for AIDS Prevention and Control, Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
- 期: 卷 82, 编号 11 (2010)
- 页面: 27-32
- 栏目: Editorial
- URL: https://journal-vniispk.ru/0040-3660/article/view/30714
- ID: 30714
如何引用文章
全文:
详细
The paper gives the results of the largest international studies demonstrating the efficacy and safety of Raltegravir as part of antiretroviral treatment (ARVT) regimens in both patients starting therapy (STARTMRK study) and those pretreated with antiretroviral drugs (BENCHMRK study). The advantage of Raltegravir over Efavirens is the lower incidence of adverse central nervous system reactions.
Based on the results of published investigations, specialists from the USA and European Union have incorporated the first HIV integrase inhibitor Raltegravir into a first-line ARTV regimen. Raltegravir is the drug of choice and should be used in special categories of patients, such as those with chronic hepatitis C or fat metabolic disturbances.
Based on the results of published investigations, specialists from the USA and European Union have incorporated the first HIV integrase inhibitor Raltegravir into a first-line ARTV regimen. Raltegravir is the drug of choice and should be used in special categories of patients, such as those with chronic hepatitis C or fat metabolic disturbances.
作者简介
Aleksey Kravchenko
Федеральный научно-методический центр по профилактике и борьбе со СПИДом ФГУН Центральный НИИ эпидемиологии Роспотребнадзора
Email: kravchenko@hivrussia.net
д-р мед. наук, проф., вед. науч. сотр., ФГУН ЦНИИЭ Роспотребнадзора, тел.: 8-495-366-05-18; Федеральный научно-методический центр по профилактике и борьбе со СПИДом ФГУН Центральный НИИ эпидемиологии Роспотребнадзора
A Kravchenko
Federal Research and Methodological Center for AIDS Prevention and Control, Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human WelfareFederal Research and Methodological Center for AIDS Prevention and Control, Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
参考
- Бартлетт Д., Галлант Д., Фам П. Клинические аспекты ВИЧ-инфекции, 2009-2010. М.: Р. Валент; 2010.
- Clinical management and treatment of HIV-infected adults in Europe, EACS Guidelines, Version 5, November, 2009 (http:/ /www.europeanaidsclinicalsociety.org).
- Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents // Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) December 1, 2009 (http://AIDSinfo.nih.gov).
- Lennox J., DeJesus E., Lazzarin A. et al. Raltegravir demonstrates durable efficacy through 96 weeks (wk): results from STARTMRK, a phase III study of raltegravir (RAL)-based vs efavirenz (EFV)-based therapy in treatment-naive HIV + patients (pts). In: 49th Interscience conference on antimicrobial agents and chemotherapy (ICAAC), Sept. 12-15 2009, San Francisco, California. San Francisco; 2009. Abstr. H-924b.
- Steigbigel R., Cooper D., Eron J. et al. 96-week results from BENCHMRK1 and 2, phase III studies of raltegravir in patients failing ART with triple-class-resistant HIV. In: 16th Conference on retroviruses and opportunistic infections (CROI), Febr. 8-11 2009, Montrйal, Canada. Montrйal, 2009. Abstr. 571b.
- Eron J., Cooper D., Steigbigel R. et al. Sustained antiretroviral effect of raltegravir at week 156 in the BENCHMRK studies and exploratory analysis of late outcomes based on early virologic responses. In: 17th Conference on retroviruses and opportunistic infections (CROI), February 16-19 2010, San Francisco, California. San Francisco; 2010. Poster-515.
- Eron J., Young B., Cooper D. A. et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375(9712): 396-407.
- Mena A., Blanco F., Cуrdoba M. et al. Hepatic safety profile of raltegravir in HIV patients with chronic hepatitis C. In: 5th International AIDS Society conference on HIV pathogenesis, treatment, and prevention (IAS 2009). July 19-22 2009. Cape Town, South Africa. Cape Town, 2009. Abstr. WePeB230.
- Покровский В. В. (ред.) Клинические рекомендации. ВИЧ-инфекция и СПИД. М.: ГЭОТАР-Мед; 2010.
补充文件
